Presentation and Status in Health Basket
| Presentation | Basket | Yarpa | Pharmasoft |
|---|---|---|---|
|
Tablets 30 X 10 mg |
|
26873 | 19429 |
|
Tablets 30 X 20 mg |
|
26874 | 19430 |
|
Tablets 30 X 40 mg |
|
59805 | 19714 |
|
Tablets 30 X 80 mg |
|
59806 | 9778 |
Related information
Indications
In patients with coronary heart disease and hypercholesterolemia to: reduce the risk of total mortality by reducing coronary death; reduce the risk of non-fatal myocardial infarction; reduce the risk for undergoing myocardial revascularization procedures; reduce the risk of stroke and transient ischemic attacks (TIA)., hyperlipidemia. Also indicated as an adjunct to diet to reduce elevated TOTAL-C, LDL-C, Apo B and TG, and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson types 11a and 11b) by lowering the LDL-C/HDL-C and the total C/HDL-C ratios. In homozygous familial hypercholesterolemia as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol, LDL-cholesterol and apolipoprotein B in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. Hypertriglyceridemia (Fredrickson type IV hyperlipidemia): for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia).
Contra-Indications
Please refer to the manufacturer for further information.
Special Precautions
Please refer to the manufacturer for further information.
Side Effects
Please refer to the manufacturer for further information.
Drug interactions
N/A.
